Mechanisms of antifungal drug resistance in Candida dubliniensis

Future Microbiology

Volumn 5, Issue 6, 2010, Pages 935-949

  Coleman, David C ^a   Moran, Gary P ^a   McManus, Brenda A ^a   Sullivan, Derek J ^a  

^a TRINITY COLLEGE DUBLIN   (Ireland)

Author keywords

5 fluorocytosine resistance; Antifungal drug resistance; Candida dubliniensis; CdCDR1; CdERG11; CdERG3; CdFCA1; CdMDR1; CdMRR1; Fluconazole resistance; Resistance mechanisms

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; ANTIRETROVIRUS AGENT; ECHINOCANDIN; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; KETOCONAZOLE; MULTIDRUG RESISTANCE PROTEIN 1; POLYENE; PYRROLE DERIVATIVE; VORICONAZOLE;

AMINO ACID SUBSTITUTION; ANTIFUNGAL ACTIVITY; ANTIFUNGAL RESISTANCE; ANTIFUNGAL SUSCEPTIBILITY; CANDIDA ALBICANS; CANDIDA DUBLINIENSIS; CANDIDIASIS; CLADISTICS; CLONAL VARIATION; COMMUNITY STRUCTURE; FUNGAL COMMUNITY; FUNGAL GENOME; FUNGAL VIRULENCE; FUNGUS ISOLATION; GENOME ANALYSIS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOCOMPROMISED PATIENT; MINIMUM INHIBITORY CONCENTRATION; MULTILOCUS SEQUENCE TYPING; MYCOSIS; NONHUMAN; POINT MUTATION; PRIORITY JOURNAL; REVIEW;

ANTIFUNGAL AGENTS; CANDIDA; DRUG RESISTANCE, FUNGAL; HUMANS; MODELS, BIOLOGICAL;

CANDIDA; CANDIDA ALBICANS; CANDIDA DUBLINIENSIS;

EID: 77953254693     PISSN: 17460913     EISSN: None     Source Type: Journal    
DOI: 10.2217/fmb.10.51     Document Type: Review

References (129)

1. Coleman DC, Bennett DE, Sullivan DJ et al.: Oral Candida in HIV infection and AIDS: new perspectives/new approaches. Crit. Rev. Microbiol. 19(2), 61-82 (1993).
2. Sullivan DJ, Henman MC, Moran GP et al.: Molecular genetic approaches to identification, epidemiology and taxonomy of non-albicans Candida species. J. Med. Microbiol. 44(6), 399-408 (1996).
3. Kibbler CC, Seaton S, Barnes RA et al.: Management and outcome of bloodstream infections due to Candida species in England and Wales. J. Hosp. Infect. 54(1), 18-24 (2003).
4. Chakrabarti A, Chatterjee SS, Rao KL et al.: Recent experience with fungaemia: change in species distribution and azole resistance. Scand. J. Infect. Dis. 41(4), 275-284 (2009).
5. Lass-Flörl C: The changing face of epidemiology of invasive fungal disease in Europe. Mycoses 52(3), 197-205 (2009).
6. Sullivan DJ, Westerneng TJ, Haynes KA, Bennett DE, Coleman DC: Candida dubliniensis sp. nov.: phenotypic and molecular characterization of a novel species associated with oral candidosis in HIV-infected individuals. Microbiology 141(7), 1507-1521 (1995).
7. Coleman DC, Sullivan DJ, Bennett DE, Moran GP, Barry HJ, Shanley DB: Candidiasis: the emergence of a novel species, Candida dubliniensis. AIDS 11(5), 557-567 (1997).
8. Sullivan D, Haynes K, Bille J et al.: Widespread geographic distribution of oral Candida dubliniensis strains in human immunodeficiency virus-infected individuals. J. Clin. Microbiol. 35(4), 960-964 (1997).
9. Coleman D, Sullivan D, Harrington B et al.: Molecular and phenotypic analysis of Candida dubliniensis: a recently identified species linked with oral candidosis in HIV-infected and AIDS patients. Oral Dis. 2(S1), S96-S101 (1997).
10. Sullivan D, Coleman D: Candida dubliniensis: characteristics and identification. J. Clin. Microbiol. 36(2), 329-334 (1998).
11. Sullivan DJ, Moran G, Donnelly S et al.: Candida dubliniensis: an update. Rev. Iberoam. Micol. 16(2), 72-76 (1999).
12. PolacheckI, Strahilevitz J, Sullivan D, Donnelly S, Salkin IF, Coleman DC: Recovery of Candida dubliniensis from non-human immunodeficiency virus-infected patients in Israel. J. Clin. Microbiol. 38(1), 170-174 (2000).
13. Pontón J, Rüchel R, Clemons KV et al.: Emerging pathogens. Med. Mycol. 38(S1), 225-236 (2000).
14. Willis AM, Coulter WA, Sullivan DJ et al.: Isolation of C. dubliniensis from insulin-using diabetes mellitus patients. J. Oral Pathol. Med. 29(2), 86-90 (2000).
15. Milan EP, de Laet Sant' Ana P, de Azevedo elo AS et al.: Multicenter prospective surveillance of oral Candida dubliniensis among adult Brazilian human immunodeficiency virus-positive and AIDS patients. Diagn. Microbiol. Infect. Dis. 41(1-2), 29-35 (2001).
16. Moragues MD, Omaetxebarria MJ, Elguezabal N et al.: Serological differentiation of experimentally induced Candida dubliniensis and Candida albicans infections. J. Clin. Microbiol. 39(8), 2999-3001 (2001).
17. Boyle BM, Sullivan DJ, Forkin C, Mulcahy F, Keane CT, Coleman DC: Candida dubliniensis candidaemia in an HIV-positive patient in Ireland. Int. J. STD AIDS 13(1), 55-57 (2002).
18. Martinez M, López-Ribot JL, Kirkpatrick WR, Coco BJ, Bachmann SP, Patterson TF: Replacement of Candida albicans with C. dubliniensis in human immunodeficiency virus-infected patients with oropharyngeal candidiasis treated with fluconazole. J. Clin. Microbiol. 40(9), 3135-3139 (2002). (Pubitemid 34977419)
19. Gee SF, Joly S, Soll DR et al.: Identification of four distinct genotypes of Candida dubliniensis and detection of microevolution in vitro and in vivo. J. Clin. Microbiol. 40(2), 556-574 (2002).
20. Bagg J, Sweeney MP, Lewis MA et al.: High prevalence of non-albicans yeasts and detection of anti-fungal resistance in the oral flora of patients with advanced cancer. Palliat. Med. 17(6), 477-481 (2003).
21. Fotedar R, Al-Hedaithy SS: Candida dubliniensis at a university hospital in Saudi Arabia. J. Clin. Microbiol. 41(5), 1907-1911 (2003).
22. Montour L, Tey R, Xu J: Isolation of Candida dubliniensis in an aboriginal community in Ontario, Canada. J. Clin. Microbiol. 41(7), 3423-3426 (2003).
23. Silva V, Cabrera M, Díaz MC, Abarca C, Hermosilla G: Prevalence of Candida albicans serotypes in blood isolates in Chile, and first report of Candida dubliniensis candidemia. Rev. Iberoam. Micol. 20(2), 46-51 (2003).
24. Yang CW, Barkham TM, Chan FY, Wang Y: Prevalence of Candida species, including Candida dubliniensis, in Singapore. J. Clin. Microbiol. 41(1), 472-474 (2003).
25. Sullivan DJ, Moran GP, Pinjon E et al.: Comparison of the epidemiology, drug resistance mechanisms, and virulence of Candida dubliniensis and Candida albicans. FEMS Yeast Res. 4(4-5), 369-376 (2004).
26. Binolfi A, Biasoli MS, Luque AG, Tosello E, Magaró HM: High prevalence of oral colonization by Candida dubliniensis in HIV-positive patients in Argentina. Med. Mycol. 43(5), 431-437 (2005).
27. Carr MJ, Clarke S, O'Connell F, Sullivan DJ, Coleman DC, O'Connell B: First reported case of endocarditis caused by Candida dubliniensis. J. Clin. Microbiol. 43(6), 3023-3026 (2005).
28. Chan-TackKM: Fatal Candida dubliniensis septicemia in a patient with AIDS. Clin. Infect. Dis. 40(8), 1209-1210 (2005).
29. Jabra-RizkMA, Johnson JK, Forrest G, Mankes K, Meiller TF, Venezia RA: Prevalence of Candida dubliniensis fungemia at a large teaching hospital. Clin. Infect. Dis. 41(7), 1064-1067 (2005).
30. Melkusovà S, Lisalovà M, PavlìkP, Bujdàkovà H: The first clinical isolates of Candida dubliniensis in Slovakia. Mycopathologia 159(3), 369-371(2005).
31. Mubareka S, Vinh DC, Sanche SE: Candida dubliniensis bloodstream infection: a fatal case in a lung transplant recipient. Transpl. Infect. Dis. 7(3-4), 146-149 (2005).
32. Sullivan DJ, Moran GP, Coleman DC: Candida dubliniensis: ten years on. FEMS Microbiol. Lett. 253(1), 9-17 (2005).
33. Tay ST, Chai HC, Na SL, Ng KP: Molecular subtyping of clinical isolates of Candida albicans and identification of Candida dubliniensis in Malaysia. Mycopathologia 159(3), 325-329 (2005).
34. Brito Gamboa A, Mendoza M, Fernández A, Díaz E: Detection of Candida dubliniensis in patients with candidiasis in Caracas, Venezuela. Rev. Iberoam. Micol. 23(2), 81-84 (2006).
35. Tekeli A, Akan OA, Koyuncu E, Dolapci I, Uysal S: Initial Candida dubliniensis isolate in Candida spp. positive haemocultures in Turkey between 2001 and 2004. Mycoses 49(1), 60-64 (2006).
36. Erköse G, Erturan Z: Oral Candida colonization of human immunodeficiency virus infected subjects in Turkey and its relation with viral load and CD4+ T-lymphocyte count. Mycoses 50(6), 485-490 (2007).
37. Jewtuchowicz VM, Mujica MT, Brusca MI et al.: Phenotypic and genotypic identification of Candida dubliniensis from subgingival sites in immunocompetent subjects in Argentina. Oral Microbiol. Immunol. 23(6), 505-509 (2008).
38. McManus BA, Coleman DC, Moran G et al.: Multilocus sequence typing reveals that the population structure of Candida dubliniensis is significantly less divergent than that of Candida albicans. J. Clin. Microbiol. 46(2), 652-664 (2008).
39. Alvarez MI, Suárez BL, Caicedo LD: Isolation of Candida dubliniensis for the first time in Cali, Colombia, and its identification with phenotyping methods. Mycopathologia 167(1), 19-24 (2009).
40. Chunchanur SK, Nadgir SD, Halesh LH, Patil BS, Kausar Y, Chandrasekhar MR: Detection and antifungal susceptibility testing of oral Candida dubliniensis from human immunodeficiency virus-infected patients. Indian J. Pathol. Microbiol. 52(4), 501-504 (2009).
41. de Araújo Navas EA, Inocêncio AC, Almeida JD et al.: Oral distribution of Candida species and presence of oral lesions in Brazilian leprosy patients under multidrug therapy. J. Oral Pathol. Med. 38(10), 764-767 (2009).
42. Gasparoto TH, Dionísio TJ, de Oliveira CE et al.: Isolation of Candida dubliniensis from denture wearers. J. Med. Microbiol. 58(7), 959-962 (2009).
43. Khlif M, Sellami H, Sellami A et al.: Candida dubliniensis: first identification in Sfax Hospital, Tunisia. Mycoses 52(2), 171-175 (2009).
44. Song X, Sun J, Støre G, Hansen BF, Olsen I: Colony morphologies, species, and biotypes of yeasts from thrush and denture stomatitis. Acta Odontol. Scand. 28, 1-8 (2009).
45. Donnelly SM, Sullivan DJ, Shanley DB, Coleman DC: Phylogenetic analysis and rapid identification of Candida dubliniensis based on analysis of ACT1 intron and exon sequences. Microbiology 145(8), 1871-1882 (1999).
46. Gilfillan GD, Sullivan DJ, Haynes K, Parkinson T, Coleman DC, Gow NA: Candida dubliniensis: phylogeny and putative virulence factors. Microbiology 144(4), 829-838 (1998).
47. Pinjon E, Sullivan D, Salkin I, Shanley D, Coleman D: Simple, inexpensive, reliable method for differentiation of Candida dubliniensis from Candida albicans. J. Clin. Microbiol. 36(7), 2093-2095 (1998).
48. Pincus DH, Coleman DC, Pruitt WR et al.: Rapid identification of Candida dubliniensis with commercial yeast identification systems. J. Clin. Microbiol. 37(11), 3533-3539 (1999).
49. Al Mosaid A, Sullivan D, Salkin IF, Shanley D, Coleman DC: Differentiation of Candida dubliniensis from Candida albicans on staib agar and caffeic acid-ferric citrate agar. J. Clin. Microbiol. 39(1), 323-327 (2001).
50. Mahmoudabadi AZ, Radcliffe CE, Coleman DC, Drucker DB: Comparison of Candida dubliniensis and C. albicans based on polar lipid composition. J. Appl. Microbiol. 93(5), 894-899 (2002).
51. Al Mosaid A, Sullivan DJ, Coleman DC: Differentiation of Candida dubliniensis from Candida albicans on Pal's agar. J. Clin. Microbiol. 41(10), 4787-4789 (2003). (Pubitemid 37259795)
52. Moran G, Stokes C, Thewes S, Hube B, Coleman DC, Sullivan D: Comparative genomics using Candida albicans DNA microarrays reveals absence and divergence of virulence-associated genes in Candida dubliniensis. Microbiology 150(10), 3363-3382 (2004).
53. Jackson AP, Gamble JA, Yeomans T et al.: Comparative genomics of the fungal pathogens Candida dubliniensis and Candida albicans. Genome Res. 19(12), 2231-2244 (2009).
54. Stokes C, Moran GP, Spiering MJ, Cole GT, Coleman DC, Sullivan DJ: Lower filamentation rates of Candida dubliniensis contribute to its lower virulence in comparison with Candida albicans. Fungal Genet. Biol. 44(9), 920-931 (2007).
55. Moran GP, MacCallum DM, Spiering MJ, Coleman DC, Sullivan DJ: Differential regulation of the transcriptional repressor NRG1 accounts for altered host-cell interactions in Candida albicans and Candida dubliniensis. Mol. Microbiol. 66(4), 915-929 (2007).
56. Enjalbert B, Moran GP, Vaughan C et al.: Genome-wide gene expression profiling and a forward genetic screen show that differential expression of the sodium ion transporter Ena21 contributes to the differential tolerance of Candida albicans and Candida dubliniensis to osmotic stress. Mol. Microbiol. 72(1), 216-228 (2009).
57. Spiering MJ, Moran GP, Chauvel Met al.: Comparative transcript profiling of Candida albicans and Candida dubliniensis identifies SFL2, a C. albicans gene required for virulence in a reconstituted epithelial infection model. Eukaryot. Cell 9(2), 251-265 (2010).
58. Hazen KC: New and emerging yeast pathogens. Clin. Microbiol. Rev. 8(4), 462-478 (1995).
59. Rex JH, Rinaldi MG, Pfaller MA: Resistance of Candida species to fluconazole. Antimicrob. Agents Chemother. 39(1), 1-8 (1995).
60. Klepser ME, Ernst EJ, Pfaller MA: Update on antifungal resistance. Trends Microbiol. (9), 372-375 (1997).
61. White TC: Increased mRNA levels of ERG16, CDR, and MDR1 correlate with increases in azole resistance in Candida albicans isolates from a patient infected with human immunodeficiency virus. Antimicrob. Agents Chemother. 41(7), 1482-1487 (1997).
62. White TC, Pfaller MA, Rinaldi MG, Smith J, Redding SW: Stable azole drug resistance associated with a substrain of Candida albicans from an HIV-infected patient. Oral Dis. 3(Suppl. 1), 102-109 (1997).
63. Müller FM, Weig M, Peter J, Walsh TJ: Azole cross-resistance to ketoconazole, fluconazole, itraconazole and voriconazole in clinical Candida albicans isolates from HIV-infected children with oropharyngeal candidosis. J. Antimicrob. Chemother. 46(2), 338-340 (2000).
64. St-Germain G, Laverdière M, Pelletier R et al.: Prevalence and antifungal susceptibility of 442 Candida isolates from blood and other normally sterile sites: results of a 2-year (1996 to 1998) multicenter surveillance study in Quebec, Canada. J. Clin. Microbiol. 39(3), 949-953 (2001).
65. Vazquez JA, Peng G, Sobel JD et al.: Evolution of antifungal susceptibility among Candida species isolates recovered from human immunodeficiency virus-infected women receiving fluconazole prophylaxis. Clin. Infect. Dis. 33(7), 1069-1075 (2001).
66. Martínez M, López-Ribot JL, Kirkpatrick WR et al.: Heterogeneous mechanisms of azole resistance in Candida albicans clinical isolates from an HIV-infected patient on continuous fluconazole therapy for oropharyngeal candidosis. J. Antimicrob. Chemother. 49(3), 515-524 (2002).
67. Morschhäuser J: The genetic basis of fluconazole resistance development in Candida albicans. Biochim. Biophys. Acta 1587(2-3), 240-248 (2002).
68. Pfaller MA, Messer SA, Boyken et al.: In vitro activities of voriconazole, posaconazole, and fluconazole against 4,169 clinical isolates of Candida spp. and Cryptococcus neoformans collected during 2001 and 2002 in the ARTEMIS global antifungal surveillance program. Diagn. Microbiol. Infect. Dis. 48(3), 201-205 (2004).
69. Sanglard D, Ischer F, Calabrese D, MajcherczykPA, Bille J: The ATP binding cassette transporter gene CgCDR1 from Candida glabrata is involved in the resistance of clinical isolates to azole antifungal agents. Antimicrob. Agents Chemother. 43(11), 2753-2765 (1999).
70. Hachem R, Hanna H, Kontoyiannis D, Jiang Y, Raad I: The changing epidemiology of invasive candidiasis: Candida glabrata and Candida krusei as the leading causes of candidemia in hematologic malignancy. Cancer 112(11), 2493-2499 (2008).
71. Pfaller MA, Diekema DJ, Gibbs DL et al.: Candida krusei, a multidrug-resistant opportunistic fungal pathogen: geographic and temporal trends from the ARTEMIS DISK Antifungal Surveillance Program, 2001 to 2005. J. Clin. Microbiol. 46(2), 515-521 (2008).
72. Pfaller MA, Messer SA, Hollis RJ: Strain delineation and antifungal susceptibilities of epidemiologically related and unrelated isolates of Candida lusitaniae. Diagn. Microbiol. Infect. Dis. 20(3), 127-133 (1994).
73. Minari A, Hachem R, Raad I: Candida lusitaniae: a cause of breakthrough fungemia in cancer patients. Clin. Infect. Dis. 32(2), 186-190 (2001). (Pubitemid 32524786)
74. Hawkins JL, Baddour LM: Candida lusitaniae infections in the era of fluconazole availability. Clin. Infect. Dis. 36(2), E14-E18 (2003).
75. Chapeland-Leclerc F, Bouchoux J, Goumar A, Chastin C, Villard J, Noël T: Inactivation of the FCY2 gene encoding purine-cytosine permease promotes cross-resistance to flucytosine and fluconazole in Candida lusitaniae. Antimicrob. Agents Chemother. 49(8), 3101-3108 (2005).
76. Florent M, Noël T, Ruprich-Robert G et al.: Nonsense and missense mutations in FCY2 and FCY1 genes are responsible for flucytosine resistance and flucytosine-fluconazole cross-resistance in clinical isolates of Candida lusitaniae. Antimicrob. Agents Chemother. 53(7), 2982-2990 (2009).
77. Joly S, Pujol C, Rysz M, Vargas K, Soll DR: Development and characterization of complex DNA fingerprinting probes for the infectious yeast Candida dubliniensis. J. Clin. Microbiol. 37(4), 1035-1044 (1999).
78. Al Mosaid A, Sullivan DJ, PolacheckI et al.: Novel 5-flucytosine- resistant clade of Candida dubliniensis from Saudi Arabia and Egypt identified by Cd25 fingerprinting. J. Clin. Microbiol. 43(8), 4026-4036 (2005).
79. Odds FC, Bougnoux ME, Shaw DJ et al.: Molecular phylogenetics of Candida albicans. Eukaryot. Cell 6(6), 1041-1052 (2007).
80. Tassel D, Madoff MA: Treatment of Candida sepsis and Cryptococcus meningitis with 5-fluorocytosine. A new antifungal agent. JAMA 206(4), 830-832 (1968).
81. Stiller RL, Bennett JE, Scholer HJ, Wall M, PolakA, Stevens DA: Correlation of in vitro susceptibility test results with in vivo response: flucytosine therapy in a systemic candidiasis model. J. Infect. Dis. 147(6), 1070-1077 (1983).
82. Vermes A, Guchelaar HJ, Dankert J: Flucytosine: a review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions. J. Antimicrob. Chemother. 46(2), 171-179 (2000).
83. McManus BA, Moran GP, Higgins JA, Sullivan DJ, Coleman DC: A Ser29Leu substitution in the cytosine deaminase Fca1p is responsible for clade-specific flucytosine resistance in Candida dubliniensis. Antimicrob. Agents Chemother. 53(11), 4678-4685 (2009).
84. Ahmad S, Khan Z, Mokaddas E, Khan ZU: Isolation and molecular identification of Candida dubliniensis from non-human immunodeficiency virus-infected patients in Kuwait. J. Med. Microbiol. 53(7), 633-637 (2004).
85. Pfaller MA, Messer SA, Boyken L, Huynh H, Hollis RJ, Diekema DJ: In vitro activities of 5-fluorocytosine against 8,803 clinical isolates of Candida spp.: global assessment of primary resistance using National Committee for Clinical Laboratory Standards susceptibility testing methods. Antimicrob. Agents Chemother. 46(11), 3518-3521 (2002).
86. Quindós G, Ruesga MT, Martín-Mazuelos E et al.: In-vitro activity of 5-fluorocytosine against 1,021 Spanish clinical isolates of Candida and other medically important yeasts. Rev. Iberoam. Micol. 21(2), 63-69 (2004).
87. Dodgson AR, Dodgson KJ, Pujol C, Pfaller A, Soll DR: Clade-specific flucytosine resistance is due to a single nucleotide change in the FUR1 gene of Candida albicans. Antimicrob. Agents Chemother. 48(6), 2223-2227 (2004).
88. Hope WW, Tabernero L, Denning DW, Anderson MJ: Molecular mechanisms of primary resistance to flucytosine in Candida albicans. Antimicrob. Agents Chemother. 48(11), 4377-4386 (2004).
89. Moran GP, Sullivan DJ, Henman MC et al.: Antifungal drug susceptibilities of oral Candida dubliniensis isolates from human immunodeficiency virus (HIV)-infected and non-HIV-infected subjects and generation of stable fluconazole-resistant derivatives in vitro. Antimicrob. Agents Chemother. 41(3), 617-623 (1997).
90. Pfaller MA, Messer SA, Gee S et al.: In vitro susceptibilities of Candida dubliniensis isolates tested against the new triazole and echinocandin antifungal agents. J. Clin. Microbiol. 37(3), 870-872 (1999).
91. Chen SC, Marriott D, Playford EG et al.: Candidaemia with uncommon Candida species: predisposing factors, outcome, antifungal susceptibility, and implications for management. Clin. Microbiol. Infect. 15(7), 662-669 (2009).
92. Giammanco GM, Pecorella S, Distefano S, Pecoraro V, Milici ME, Pizzo G: Fluconazole susceptibility of Italian Candida dubliniensis clinical isolates determined by and simplified tests. New Microbiol. 24(4), 397-404 (2001).
93. Luque AG, Biasoli MS, Tosello ME, Binolfi A, Lupo S, Magaró HM: Oral yeast carriage in HIV-infected and non-infected populations in Rosario, Argentina. Mycoses 52(1), 53-59 (2009).
94. Salgado-Parreño FJ, Alcoba-Flórez J, Arias A: In vitro activities of voriconazole and five licensed antifungal agents against Candida dubliniensis: comparison of CLSI M27-A2, Sensititre YeastOne, diskdiffusion, and Etest methods. Microb. Drug Resist. 12(4), 246-251 (2006).
95. Moran GP, Sanglard D, Donnelly SM, Shanley DB, Sullivan DJ, Coleman DC: Identification and expression of multidrug transporters responsible for fluconazole resistance in Candida dubliniensis. Antimicrob. Agents Chemother. 42(7), 1819-1830 (1998).
96. Quindós G, Carrillo-Muñoz AJ, Arévalo MP et al.: In vitro susceptibility of Candida dubliniensis to current and new antifungal agents. Chemotherapy 46(6), 395-401 (2000).
97. Ruhnke M, Schmidt-Westhausen A, Morschhäuser J: Development of simultaneous resistance to fluconazole in Candida albicans and Candida dubliniensis in a patient with AIDS. J. Antimicrob. Chemother. 46(2), 291-295 (2000).
98. Kantarcioglu AS, Yücel A: The presence of fluconazole-resistant Candida dubliniensis strains among Candida albicans isolates from immunocompromised or otherwise debilitated HIV-negative Turkish patients. Rev. Iberoam. Micol. 19(1), 44-48 (2002).
99. Jewtuchowicz VM, Mujica MT, Brusca MI et al.: Phenotypic and genotypic identification of Candida dubliniensis from subgingival sites in immunocompetent subjects in Argentina. Oral Microbiol. Immunol. 23(6), 505-509 (2008).
100. Chunchanur SK, Nadgir SD, Halesh LH, Patil BS, Kausar Y, Chandrasekhar MR: Detection and antifungal susceptibility testing of oral Candida dubliniensis from human immunodeficiency virus-infected patients. Indian J. Pathol. Microbiol. 52(4), 501-504 (2009).
101. Sanglard D, Kuchler K, Ischer F, Pagani JL, Monod M, Bille J: Mechanisms of resistance to azole antifungal agents in Candida albicans isolates from AIDS patients involve specific multidrug transporters. Antimicrob. Agents Chemother. 39(11), 2378-2386 (1995).
102. Sanglard D, Ischer F, Monod M, Bille J: Susceptibilities of Candida albicans multidrug transporter mutants to various antifungal agents and other metabolic inhibitors. Antimicrob. Agents Chemother. 40(10), 2300-2305 (1996).
103. Sanglard D, Ischer F, Monod M, Bille J: Cloning of Candida albicans genes conferring resistance to azole antifungal agents: characterization of CDR2, a new multidrug ABC transporter gene. Microbiology 143(2), 405-416 (1997).
104. Wirsching S, Moran GP, Sullivan DJ, Coleman DC, Morschhäuser J: MDR1-mediated drug resistance in Candida dubliniensis. Antimicrob. Agents Chemother. 45(12), 3416-3421 (2001).
105. Moran G, Sullivan D, Morschhäuser J, Coleman D: The Candida dubliniensis CdCDR1 gene is not essential for fluconazole resistance. Antimicrob. Agents Chemother. 46(9), 2829-2841 (2002).
106. Pinjon E, Jackson CJ, Kelly SL et al.: Reduced azole susceptibility in genotype 3 Candida dubliniensis isolates associated with increased CdCDR1 and CdCDR2 expression. Antimicrob. Agents Chemother. 49(4), 1312-1318 (2005).
107. Franz R, Kelly SL, Lamb DC, Kelly DE, Ruhnke M, Morschhäuser J: Multiple molecular mechanisms contribute to a stepwise development of fluconazole resistance in clinical Candida albicans strains. Antimicrob. Agents Chemother. 42(12), 3065-3072 (1998).
108. McManus BA, Sullivan DJ, Moran GP et al.: Genetic differences between avian and human isolates of Candida dubliniensis. Emerg. Infect. Dis. 15(9), 1467-1470 (2009).
109. Selmecki A, Forche A, Berman J: Aneuploidy and isochromosome formation in drug-resistant Candida albicans. Science 313(5785), 367-370 (2006).
110. Coste A, Selmecki A, Forche A et al.: Genotypic evolution of azole resistance mechanisms in sequential Candida albicans isolates. Eukaryot. Cell 6(10), 1889-1904 (2007).
111. Joly S, Pujol C, Soll DR: Microevolutionary changes and chromosomal translocations are more frequent at RPS loci in Candida dubliniensis than in Candida albicans. Infect. Genet. Evol. 2(1), 19-37 (2002).
112. Perea S, López-Ribot JL, Wickes BL et al.: Molecular mechanisms of fluconazole resistance in Candida dubliniensis isolates from human immunodeficiency virus-infected patients with oropharyngeal candidiasis. Antimicrob. Agents Chemother. 46(6), 1695-1703 (2002).
113. Sanglard D, Ischer F, Koymans L, Bille J: Amino acid substitutions in the cytochrome P-450 lanosterol 14a-demethylase (CYP51A1) from azole-resistant Candida albicans clinical isolates contribute to resistance to azole antifungal agents. Antimicrob. Agents Chemother. 42(2), 241-253 (1998).
114. Perea S, López-Ribot JL, KirkpatrickWR et al.: Prevalence of molecular mechanisms of resistance to azole antifungal agents in Candida albicans strains displaying high-level fluconazole resistance isolated from human immunodeficiency virus-infected patients. Antimicrob. Agents Chemother. 45(10), 2676-2684 (2001).
115. Morschhäuser J, Barker KS, Liu TT, BlaB-Warmuth J, Homayouni R, Rogers PD: The transcription factor Mrr1p controls expression of the MDR1 efflux pump and mediates multidrug resistance in Candida albicans. PLoS Pathog. 3(11), e164 (2007).
116. Dunkel N, Blass J, Rogers PD, Morschhäuser J: Mutations in the multi-drug resistance regulator MRR1, followed by loss of heterozygosity, are the main cause of MDR1 overexpression in fluconazole-resistant Candida albicans strains. Mol. Microbiol. 69(4), 827-840 (2008).
117. Schubert S, Rogers PD, Morschhäuser J: Gain-of-function mutations in the transcription factor MRR1 are responsible for overexpression of the MDR1 efflux pump in fluconazole-resistant Candida dubliniensis strains. Antimicrob. Agents Chemother. 52(12), 4274-4280 (2008).
118. Fleischhacker M, Pasligh J, Moran G, Ruhnke M: Longitudinal genotyping of Candida dubliniensis isolates reveals strain maintenance, microevolution and the emergence of itraconazole resistance. J. Clin. Microbiol. (2010) (Epub ahead of print).
119. Pinjon E, Moran GP, Jackson CJ et al.: Molecular mechanisms of itraconazole resistance in Candida dubliniensis. Antimicrob. Agents Chemother. 47(8), 2424-2437 (2003).
120. Sanglard D, Coste A, Ferrari S: Antifungal drug resistance mechanisms in fungal pathogens from the perspective of transcriptional gene regulation. FEMS Yeast Res. 9(7), 1029-1050 (2009).
121. Morschhäuser J: Regulation of multidrug resistance in pathogenic fungi. Fungal Genet. Biol. 47(2), 94-106 (2010).
122. Melkusová S, Bujdáková H, Volleková A, Myoken Y, Mikami Y: The efficiency of the benzothiazole APB, the echinocandin micafungin, and amphotericin B in fluconazole-resistant Candida albicans and Candida dubliniensis. Pharmazie 59(7), 573-574 (2004).
123. Pfaller MA, Diekema DJ, Messer SA, Boyken L, Hollis RJ, Jones RN: In vitro susceptibilities of rare Candida bloodstream isolates to ravuconazole and three comparative antifungal agents. Diagn. Microbiol. Infect. Dis. 48(2), 101-105 (2004).
124. Quindós G, Villar-Vidal M, Eraso E: Activity of micafungin against Candida biofilms. Rev. Iberoam. Micol. 26(1), 49-55 (2009).
125. Szabo Z, Borbely A, Kardos G et al.: In vitro efficacy of amphotericin B, 5-fluorocytosine, fluconazole, voriconazole and posaconazole against Candida dubliniensis isolates using time-kill methodology. Mycoses (2010) (In Press).
126. Desnos-Ollivier M, Bretagne S, Raoux D, Hoinard D, Dromer F, Dannaoui E; European Committee on Antibiotic Susceptibility Testing: Mutations in the fks1 gene in Candida albicans, C. tropicalis, and C. krusei correlate with elevated caspofungin MICs uncovered in AM3 medium using the method of the European Committee on Antibiotic Susceptibility Testing. Antimicrob. Agents Chemother. 52(9), 3092-3098 (2008).
127. Wiederhold NP, Grabinski JL, Garcia-Effron G, Perlin DS, Lee SA: Pyrosequencing to detect mutations in FKS1 that confer reduced echinocandin susceptibility in Candida albicans. Antimicrob. Agents Chemother. 52(11), 4145-4148 (2008).
128. Garcia-Effron G, Lee S, ParkS, Cleary JD, Perlin DS: Effect of Candida glabrata FKS1 and FKS2 mutations on echinocandin sensitivity and kinetics of 1,3-b-d-glucan synthase: implication for the existing susceptibility breakpoint. Antimicrob. Agents Chemother. 53(9), 3690-3699 (2009).
129. McGovern E, Fleming P, Costigan C, Dominguez M, Coleman DC, Nunn J: Oral health in Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (APECED). Eur. Arch. Paediatr. Dent. 9(4), 236-244 (2008).